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• To review the published data on predisposing risk factors
for cancer treatment-induced haemorrhagic cystitis (HC)
and the evidence for the diﬀerent preventive and
therapeutic measures that have been used in order to help
clinicians optimally deﬁne and manage this potentially
serious condition.
• Despite recognition that HC can be a signiﬁcant
complication of cancer treatment, there is currently a lack of
UK-led guidelines available on how it should optimally be
deﬁned and managed.
• A systematic literature review was undertaken to evaluate
the evidence for preventative measures and treatment
options in the management of cancer treatment-induced
HC.
• There is a wide range of reported incidence due to
several factors including variability in study design
and quality, the type of causal agent, the grading
of bleeding, and discrepancies in deﬁnition
criteria.
• The most frequently reported causal factors are
radiotherapy to the pelvic area, where HC has been
reported in up to 20% of patients, and treatment with
cyclophosphamide and bacillus Calmette-Guérin, where the
incidence has been reported as up to 30%.
• Mesna (2-mercaptoethane sodium sulphonate),
hyperhydration and bladder irrigation have been
the most frequently used prophylactic measures to
prevent treatment-related cystitis, but are not always
eﬀective.
• Cranberry juice is widely cited as a preventative measure
and sodium pentosanpolysulphate as a treatment, although
the evidence for both is very limited.
• The best evidence exists for intravesical hyaluronic acid
as an eﬀective preventative and active treatment, and
for hyperbaric oxygen as an equally eﬀective treatment
option.
• The lack of robust data and variability in treatment
strategies used highlights the need for further research, as
well as best practice guidance and consensus on the
management of HC.
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Introduction
Haemorrhagic cystitis (HC) can be either acute or chronic,
and be caused by chemotherapeutic drugs, radiation therapy
(RT), or exposure to chemicals, e.g. dyes or insecticides [1].
In transplantation settings, HC is typically associated with
haematopoietic stem cell transplant (HSCT), but can also
occur, albeit rarely, in solid organ recipients [2]. It is thought
that a defect in the glycosaminoglycan (GAG) layer, which
coats the uroepithelium and provides the initial barrier
for physiological protection, may be the ﬁrst step in its
development [3]. Once injured or defective, the GAG layer
loses its barrier properties, becomes permeable, and allows the
inﬂammatory and hypersensitisation cycle to thrive [3].
With a tendency towards more aggressive treatment of cancer,
including the use of HSCT, chemical- and RT-induced HC can
be considered an increasingly important clinical issue, not
least because it is a challenging condition to treat. However,
few epidemiological studies have been undertaken and
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therefore, the exact prevalence is unknown. Treatment can be
problematic, especially in elderly patients who may be frail
and have comorbidities [4], and because the condition often
responds inadequately to the usual symptomatic therapies. In
severe cases, HC is associated with signiﬁcant morbidity,
prolonged hospitalisation and occasional mortality, and may
require more aggressive measures, e.g. supravesical urinary
diversion, vesical artery selective embolization, and cystectomy
[5]. Furthermore, as the global burden of cancer is forecast
to rise, primarily due to ageing and growth of the world’s
population [6], it is likely that the incidence of HC will rise
too because of the increasing use of RT and chemotherapy.
However, there is currently a lack of consensus about the best
treatment for patients with chemical- and RT-induced HC, as
well as a lack of UK-led guidelines available on how it should
optimally be deﬁned and managed.
The aim of the present article is to review the predisposing
risk factors for chemical- and RT-induced HC and the
evidence for the diﬀerent therapeutic and preventive measures
that have been used to help clinicians better manage this
potentially disabling condition.
Methods
A comprehensive literature search was undertaken in PubMed
to retrieve studies and case reports, published in English,
relating to the treatment of chemical- and RT-induced HC
from 1980 to September 2012. The search was conducted
using a comprehensive search strategy, including the terms
‘haemorrhagic cystitis’, ‘chemical cystitis’, ‘radiation cystitis’ in
combination with ‘risk factors’, ‘chemotherapeutic drugs’,
‘hyaluronic acid’, ‘sodium hyaluronate’, ‘hyperbaric
oxygen’, ‘mesna’, ‘hyperhydration’, ‘bladder irrigation’,
‘pentosanpolysulphate’, ‘oestrogen’, ‘recombinant factor VII’,
‘formalin’, and ‘prostaglandin’. The search results were
supplemented by review of the bibliographies of key articles for
additional studies, inclusion of relevant abstracts presented at
key meetings, as well as expert input, to help ensure the capture
of all pertinent data.
Results
Incidence and Reported Predisposing Risk Factors
HC has multiple potential causes, including chemical toxins
and radiation. As well as variability in the propensity of the
causative factor to induce HC, diﬀerences in deﬁnition criteria
are in part responsible for the wide range of reported
incidences [7], with some degree of HC aﬀecting up to 100%
of patients in some studies. The available scoring systems for
the severity of toxicity also use variable criteria, further
complicating the comparative assessment of agents and studies
in which they are used.
HC has a spectrum of manifestations that range from
non-visible (or microscopic) haematuria to gross (visible)
haematuria with clots, and can be graded as mild, moderate
or severe according to the degree of pain and amount of
haematuria [8]. A more comprehensive grading system for
the severity of HC has been proposed by Droller et al. [9]
(Table 1) and is used in many of the clinical trials presented.
In rare cases it may be severe and life-threatening, requiring
cystectomy [10]. Although most studies focus on severe
(grades III–IV) HC, grade I HC can cause disabling
symptoms, e.g. frequency, urgency and pelvic pain, often
localised to the bladder or urethra.
Chemical-induced HC
A wide variety of chemotherapeutic drugs may cause
chemical-induced HC (Table 2), most signiﬁcantly the
oxazaphosphorine compounds, cyclophosphamide [11–13]
and ifosfamide [14,15]. Cyclophosphamide is used in the
treatment of B cell malignant diseases and some solid
tumours, conditioning before bone marrow transplantation,
and in the treatment of certain immuno-inﬂammatory
conditions, e.g.Wegener’s granulomatosis, rheumatoid arthritis
and systemic lupus erythematosus [1,4]. The cause of bladder
damage has been linked to acrolein, a urinary metabolite of
cyclophosphamide and ifosfamide [16]. HC can develop weeks
or months after treatment in 20–25% of patients who receive
high-dose cyclophosphamide [17]. However, ifosfamide has a
greater tendency to produce this complication possibly
because of the generally higher doses administered, which
result in higher amounts of acrolein and the additional
excretion of chloroacetaldehyde [14].
Table 1 Grading of HC as defined by Droller et al. [9].
Grade Symptoms
I Non-visible haematuria
II Macroscopic haematuria
III Macroscopic haematuria with small clots
IV Gross haematuria with clots causing urinary tract obstruction requiring
instrumentation for clot evacuation
Table 2 Frequently reported causes of chemical- and RT-induced HC.
Chemotherapeutic agents Busulfan
Cyclophosphamide
Idarubicin
Ifosfamide
Paclitaxel/carboplatin therapy
Intravesical chemotherapy Doxorubicin
Epirubicin
Mitomycin C
Other therapeutic agents and environmental toxins BCG
Gentian violet
Ketamine hydrochloride
Tiaprofenic acid
Topical agents
RT Including brachytherapy
Review
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Early-onset HC has been linked to toxic eﬀects of
chemo-irradiative agents used in the conditioning regimen for
HSCT, e.g. cyclophosphamide and busulfan, and usually starts
within 48–72 h after their use [1,18]. There is a wide range of
reported incidence of chemotherapy-induced HC, from <10%
to 35% [19–21]. In a retrospective, single-centre survey of 834
patients who underwent allogeneic stem cell transplantation,
Grades II–V and III–V HC, according to the NCI Common
Terminology Criteria for Adverse Events [22], developed in
13.1% and 3.2% of patients, respectively. HC started on a
median (range) of 35 (0-166) days after transplant and
persisted for 23 (2–270) days [23]. Clinical data also show
that diﬀerent conditioning regimens [24–26] and type of
malignancy [27] may aﬀect the development of HC. In a
meta-analysis of 18 comparative studies totalling 3172
patients, the busulfan/cyclophosphamide regimen was
associated with higher rates of HC than the total body
irradiation-cyclophosphamide regimen [24]. Interestingly,
in a multivariate analysis by Tsuboi et al. [19], prophylactic
administration of 2-mercaptoethane sodium sulphonate
(mesna) (P = 0.01) and bladder irrigation (P < 0.001)
increased early-onset HC after stem cell transplantation
by an odds ratio of 5.5 (P = 0.01) and 9.5-times (P < 0.001),
respectively.
Several other anti-cancer drugs can result in urothelial GAG
loss [28]. BCG is currently regarded as the most eﬀective
intravesical treatment for superﬁcial TCC, and is also given
to reduce recurrence and progression rates after surgical
debulking or removal of more extensive tumours. However,
cystitis is a common side-eﬀect, occurring in ≈80% of
BCG-treated patients [29], while haematuria occurs in an
estimated 20%, and LUTS in an estimated 71% of patients
receiving maintenance BCG [30]. In a review of the evidence
supporting the need for maintenance BCG, cases of cystitis
and the perceived risk of adverse events, including cystitis,
were both cited as reasons for poor compliance and early
discontinuation of therapy [29]. This ﬁnding is particularly
important for patient management when one considers that
patients who fail BCG maintenance therapy will often go on to
require radical cystectomy for ultimate management of their
bladder cancer [31].
Cases of HC have also been reported with the use of other
therapeutic agents, recreational drugs and environmental
toxins, including intravesical chemotherapy with doxorubicin,
epirubicin and mitomycin C [32,33], tiaprofenic acid [34,35],
gentian violet [36], ketamine [37], and less commonly, with
exposure to certain industrial chemicals, e.g. the pesticide
chlorodimeform [38], and topical agents [1].
RT-induced HC
Radiation to the pelvic area can result in both acute and
chronic bladder injuries [39], and can lead to RT-induced HC,
which is a potentially devastating side-eﬀect that develops in a
small but signiﬁcant proportion of the treated population
(≈5–10%) [40]. However, the incidence depends on the series,
grading system and the method of calculation that have been
used [40]. RT-induced HC can occur long after RT has ended,
from 2 months to 15 years later [41]. In the BC2001 study, late
toxicity was measured with the Radiation Therapy Oncology
Group (RTOG) and Late Eﬀects of Normal Tissue (Subjective,
Objective, and Management elements) (LENT/SOM) criteria
in 360 patients with muscle-invasive bladder cancer, who were
treated either with RT, or RT plus chemotherapy (ﬂuorouracil
and mitomycin C). Grade 3 or 4 LENT/SOM genitourinary
toxicity (excluding sexual dysfunction) occurred in 16.0% of
RT- and 16.9% of chemoradiotherapy-treated patients at 1
year [42].While Grade 3 or 4 RTOG toxicity occurred in only
3.3% and 1.3% of patients, respectively, all these adverse events
concerned genitourinary symptoms [42].
The clinical manifestations of late RT HC include urinary
frequency, urgency, dysuria, haematuria, reduced bladder
capacity, sphincter dysfunction, reduced bladder capacity,
and bladder perforation [40]. Severe manifestations of the
condition can result in surgical procedures, e.g. urinary
diversion, with or without cystectomy [43]. The pathogenesis
of RT-induced cystitis originates as a progressive obliteration
of the small blood vessels of the bladder wall with consequent
development of hypoxia and tissue damage [41].
Prevention and Treatment of HC
Hyperhydration and Continuous Bladder Irrigation
Mesna, hyperhydration and bladder irrigation appear to
be the most frequently used prophylactic measures for
treatment-related HC, with varying, often disappointing,
results [44–52] (Table 3). For continuous bladder irrigation, it
is vital that clots are evacuated before therapy as the success of
subsequent irrigation often depends upon the thoroughness of
this procedure [5].
Turkeri et al. [45] reported that continuous bladder irrigation
signiﬁcantly decreased the frequency of HC in patients
receiving busulfan and cyclophosphamide as a preparative
regimen for bone marrow transplant (BMT) compared with
no bladder irrigation (23% vs 53%, respectively; P < 0.004).
Similar ﬁndings were reported by Hadjibabaie et al. [44] in a
non-randomised, controlled study of HSCT patients who
received mesna, hydration, and alkalisation regimens. HC
occurred in fewer patients who received continuous bladder
irrigation than in those who did not (32% vs 50%, respectively;
P = 0.11). Continuous bladder irrigation was also found to
signiﬁcantly reduce the mean duration of HC (10 vs 18 days;
P = 0.02) and the duration of hospitalisation (30.2 vs 39.6
days; P < 0.001) [44]. In a study by Trotman et al. [49], the
overall incidence of HC in HSCT patients using a prophylactic
regimen of hyperhydration and forced diuresis was 18.2%.
Treatment of chemical- and radiation-induced haemorrhagic cystitis
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Grade III or IV HC, based on the system devised by Droller
et al. [9], occurred in 3.4% of patients. Of potential
signiﬁcance, a randomised study by Atkinson et al. [48]
showed that bladder irrigation did not minimise the risk of
HC in patients receiving allogeneic BMT as a treatment for
haematological malignancy.
Mesna
Other routine methods of preventing chemical-induced HC
include the use of mesna, which was speciﬁcally developed to
bind acrolein in the urine. Mesna has been extensively
investigated in the management of cyclophosphamide- and
ifosfamide-induced HC with variable results [15,50–57]. It is
also unclear whether the addition of mesna therapy to
hyperhydration provides greater protection in BMT patients
who are exposed to cyclophosphamide. Shepherd et al. [51]
concluded that both approaches were equally eﬀective in
preventing cyclophosphamide-induced HC in BMT patients.
Nevertheless, HC was still seen in 33% of patients who
received mesna prophylaxis [51]. Similar ﬁndings were
reported by Vose et al. [52] in a prospective randomised trial
of mesna and continuous bladder irrigation.Whilst the overall
incidence of haematuria of any grade was signiﬁcantly higher
in the bladder-irrigation group compared with the mesna
group (76% vs 53%; P = 0.007), the incidence of grade III and
IV haematuria was the same in both treatment groups (18%;
statistically non-signiﬁcant) [52]. Less convincing data were
reported by Murphy et al. [50] who failed to show a beneﬁt in
adding mesna to hyperhydration in preventing
cyclophosphamide-induced HC. Other authors have also
found that mesna prophylaxis does not completely prevent
bladder damage [15] and possibly has a toxic eﬀect on bladder
mucosa [19].
Intravesical Therapy
Despite prophylactic hyperhydration, continuous bladder
irrigation or use of mesna, some BMT patients may have
refractory HC and require alternative treatment regimens [58].
Several intravesical therapies have been evaluated including
chondroitin sulphate, sodium hyaluronate, prostaglandins
(PGE1 PGE2, and PGF2α), formalin, and alum irrigation
(Table 4) [58–68].
Chondroitin sulphate
Most of the published studies on the use of chondroitin
sulphate have evaluated its use in the treatment of interstitial
cystitis/painful bladder syndrome. Based on animal studies,
Hazewinkel et al. [59] hypothesised that prophylactic
installation of chondroitin sulphate in patients undergoing RT
for gynaecological malignancies may limit the risk of RT
cystitis symptoms. In their pilot study, the eﬃcacy of
chondroitin sulphate was evaluated in 20 patients; 10 received
weekly intravesical installations and 10 were controls. The
acceptability of instillations and bladder pain were evaluated
using a visual analogue scale (VAS). The patients receiving
chondroitin sulphate reported less bothersome symptoms and
the treatment was well tolerated. The instillations also
appeared to reduce overactive bladder symptoms during the
Table 3 Summary of the key studies for bladder irrigation, hyperhydration and forced diuresis and mesna in the prevention of chemical- and
RT-induced cystitis.
Author Study design Patients, n Treatment Incidence of HC,%
(P-value)
Adverse effects, % (P-value)
Bladder irrigation
Hadjibabaie et al. (2008) [44] Non-randomised,
controlled
HSCT patients, 40 Bladder irrigation vs
no bladder irrigation
32 vs 50 (NS) UTI: 32.5 vs 20.0 (NS)
Turkeri et al. (1995) [45] Retrospective HSCT patients, 199 Bladder irrigation vs
no bladder irrigation
23 vs 53 (<0.004) UTI: 16.0 vs 14.0 (NS)
Moderate to severe discomfort and
bladder spasms: 6.0 (NS)
Atkinson et al. (1991) [48] Prospective,
randomised
BMT patients, 22 Bladder irrigation vs
no bladder irrigation
48 vs 29*
52 vs 38† (NS, irrigation
vs no irrigation)
Not reported
Hyperhydration and forced diuresis
Trotman et al. (1999) [49] Prospective HSCT or BMT
patients, 681
Hyperhydration and
forced diuresis
HC: 18.2
Grade 3 or 4: 3.4
Not reported
Mesna
Murphy et al. (1994) [50] Retrospective BMT patients, 227 Hyperhydration + mesna
vs hyperhydration
alone
16 vs 8 (0.08) One patient receiving
hyperhydration alone developed
a bladder perforation, requiring
surgical repair
Vose et al. (1993) [52] Prospective,
randomised
BMT patients, 200 Mesna vs bladder
irrigation
18 vs 18 (NS)‡ UTI: 14 vs 27 (0.03)
Shepherd et al. (1991) [51] Randomised BMT patients, 100 Mesna vs hyperhydration 33 vs 20 (NS) No unexpected toxicities
NS, not statistically signiﬁcant. *Patients receiving busulfan + cyclophosphamide + RT or cyclophosphamide + RT; †Patients receiving busulfan + cyclophosphamide; ‡Grade III/IV
haematuria.
Review
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period of RT. These ﬁndings support those of an earlier
multi-national, multicentre, prospective observational clinical
trial of patients with chronic forms of cystitis associated with a
possible GAG layer deﬁcit, including RT-induced cystitis [69].
However, larger trials are required to speciﬁcally assess the
evidence in support of the prophylactic use of chondroitin
sulphate in patients undergoing RT.
Sodium hyaluronate
Sodium hyaluronate, a derivative of hyaluronic acid, has been
developed to temporarily replenish the deﬁcient GAG layer [7]
and has been used successfully in the treatment of refractory
interstitial cystitis [70,71] and more recently in preventing and
treating chemical- and RT-induced HC [7,60–63,72–74]. Data
from a retrospective study by Delgado et al. [62], which
assessed toxicity using the RTOG/European Organisation for
the Research and Treatment of Cancer (EORTC) Radiation
Toxicity Score show that weekly instillations of sodium
hyaluronate in patients receiving RT for gynaecological
tumours decreased RT-induced toxicity. In a 5-year follow-up
study, Samper Ots et al. [63] also found that, compared with
no sodium hyaluronate, intravesical installation of hyaluronic
acid before each brachytherapy session signiﬁcantly reduced
the incidence of RT-induced cystitis in patients with cervical
and endometrial cancer after the second (20.8% vs 40.4%)
and fourth session (10.9% vs 31.9%) (P < 0.05, for both
comparisons). Over the whole study period, the percentage
of patients presenting vesical toxicity of grade ≥2 was
signiﬁcantly lower in the sodium hyaluronate group (2.08% vs
12.8%; P < 0.05).
Further data from a prospective study by Sommariva et al. [61]
show that sodium hyaluronate also relieves the symptoms of
chemo- or RT-induced cystitis. In all, 69 consecutive patients
who had symptoms of cystitis after RT for prostatic cancer or
after intravesical BCG or mitomycin C were given intravesical
instillations of sodium hyaluronate and cortisone. Overall, 67
(97%) patients reported complete relief of dysuria and pain,
which was assessed using a VAS. Patients with chemical-
induced cystitis were found to respond slightly better than
those who had RT-induced cystitis. Shao et al. [60] have also
shown that intravesical instillation of sodium hyaluronate is as
eﬀective as hyperbaric oxygen (HBO) therapy in the treatment
of RT-induced cystitis. In this randomised study of 36 patients
with pelvic malignancies, there was no statistical diﬀerence
between the two groups in the improvement rate (complete
response and partial response) at 6, 12 and 18 months after
treatment. However, whilst the decrease in frequency vs
baseline was signiﬁcant in both groups 6 months after
treatment, it was signiﬁcant only in the sodium hyaluronate
group 12 months after therapy. This treatment strategy was
well tolerated and resulted in a sustained decrease of bladder
bleeding, pelvic pain and frequency of voiding for ≥12 months
[60].
Prostaglandin
Data from several published case series [58,64] and case
reports [75–78] suggest that intravesical prostaglandins (PGE1
PGE2, and PGF2α) may be useful to prevent or treat HC
secondary to RT or cyclophosphamide therapy. Although the
exact mechanism of action is unclear, the prostaglandins may
work by causing smooth muscle contraction of the blood
vessels in the mucosa and submucosa, through membrane
stabilisation, or by induction of haemostasis with platelet
aggregation [58].
Ippoliti et al. [58] evaluated the use of a F2α analogue in 24
adult BMT recipients with grade 3 or 4 HC who had received
a conditioning regimen of cyclophosphamide administered
with hyperhydration and mesna. Overall, 15 (63%) patients
responded to treatment, with a median time to response of 3
days. However, nine of these patients (37.5%) had a recurrence
of HC at a median of 7 days later. These results were
comparable to other small series [64]. The main reported
side-eﬀect of prostaglandins appears to be the occurrence of
bladder spasm [58,64].
Formalin
Intravesical formalin installation has been evaluated for the
treatment of HC secondary to RT-induced cystitis [65–67] and
cyclophosphamide therapy [67], and has been shown to be
eﬀective in controlling severe bladder haemorrhage after RT of
the pelvis [65,67]. In a retrospective review of 35 patients with
RT-induced HC, formalin therapy resulted in a complete
response in 89% of patients [66]. However, treatment is
dose-dependent [65]. There have also been reports of major
complications (e.g. anuria, vesicle ﬁstula) and minor
complications (e.g. fever, transient tachycardia) after
treatment, and recurrent haematuria, as well as probable fatal
toxicity [65,66].
Alum irrigation
Alum irrigation was ﬁrst reported in 1982, when it was
successfully used to treat six patients with massive bladder
haemorrhage secondary to RT cystitis, bladder carcinoma and
HC [79]. Since then, there have been several reports on the use
of alum irrigation in the management of cyclophosphamide-
and RT-induced HC with varying degrees of success
[68,80,81]. There have also been several case reports of
aluminium toxicity after intravesical alum irrigation for HC in
children [82–84]; therefore, vigilance is needed to avoid these
toxic eﬀects [68].
Systemic Treatments
Systemic treatments, e.g. HBO, oestrogen, sodium
pentosanpolysulphate, recombinant factor VII or VIII, and
aminocaproic acid have been used with some success in the
treatment of HC (Table 5) [39,41,85–92].
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HBO therapy
HBO therapy promotes capillary angiogenesis and the
healing process in damaged tissue and has been extensively
evaluated in the management of adults with RT-induced
[41,85,86,93–97] and cyclophosphamide-induced [87,88,98]
HC. Nakada et al. [85] and Oliai et al. [86] recently reported
favourable outcomes in patients treated with HBO therapy for
RT-induced HC. Similar ﬁndings were also reported in a
prospective study by Vilar et al. [41]. In all, 14 patients
received HBO treatment for the ﬁrst time, whereas 24 had
received previous treatment with HBO. After a mean (range)
follow-up of 36.3 (12–60) months, haematuria was completely
resolved in 36 (94.7%) patients [41]. Conversely, Mohamad
Al-Ali et al. [89] found that few patients recovered from
HC after HBO therapy. Furthermore, patients treated with
HBO had a signiﬁcantly lower cure rate of post-RT HC in
comparison with patients who did not receive HBO.
Although much of the research has focussed on RT-induced
cystitis, there have been several recent case reports on the use
of HBO in the management of cyclophosphamide-induced
HC. Davis et al. [87] reviewed the case records of six patients
with life-threatening haemorrhage and reported that bleeding
ceased in all patients after 14–40 treatments without
complications. Similarly, Ajith Kumar et al. [88] retrospectively
reviewed the case notes of two patients with drug-induced HC
and reported that HBO therapy resulted in complete cessation
of bleeding in both cases, with no side-eﬀects noted during the
course of therapy. There are also case reports concerning the
successful use of HBO for intractable, refractory HC in
patients with systemic lupus erythematosus [99] and
Wegener’s granulomatosis [100]
Oestrogen
Several small series and case reports have reported that HC
secondary to RT or cyclophosphamide therapy has been
successfully treated with oestrogen [90,91,101,102]. Heath
et al. [90] reported that eight out of 10 children and
adolescents treated initially with intravenous oestrogen and
then oral oestrogen after 2 or 3 days had a signiﬁcant
reduction in their symptoms after commencing therapy. In
another series, Ordemann et al. [91] reported that, after
treatment with oral oestrogen, haematuria resolved in two of
four adult patients with mild HC and four of ﬁve patients with
severe HC. In all the case reports, oestrogen therapy appeared
to be generally well tolerated [90,91,101,102]. Potential adverse
eﬀects of long-term exposure to oestrogens include an
increased risk of cancer [91].
Sodium pentosanpolysulphate
Sodium pentosanpolysulphate is a semi-synthetic GAG similar
to heparin with anticoagulant properties and ﬁbrinolytic
eﬀects [5]. This treatment has had some success in small series
and case reports in treating patients who have developed HC
secondary to RT or cyclophosphamide therapy [103–105], but
the patient series have been limited in size. In a larger study,
Sandhu et al. [39] retrospectively reviewed the pharmacy
records of 60 patients with HC; of these patients, 53 had
received radical RT for pelvic malignancy and seven had
received systemic cyclophosphamide. After treatment with
sodium pentosanpolysulphate, the dose was gradually reduced
in 21 patients and treatment was discontinued in a further 10
patients because the haematuria stopped completely. Although
the safety and eﬃcacy of sodium pentosanpolysulphate has
not been established in paediatric patients [5], a recent
retrospective case note review of children with HC after stem
cell transplant/chemotherapy reported that early identiﬁcation,
avoidance of urethral catheterisation, and use of sodium
pentosanpolysulphate signiﬁcantly reduces blood transfusion
requirements and mortality from HC [103].
Recombinant factor VIIa/factor XIII
Several case reviews and case reports have suggested a
potential role for recombinant factor VII or XIII in the
treatment of cyclophosphamide- and RT-induced HC
[106–109]. Ashrani et al. [92] reported the results of a pilot
study using high-dose activated recombinant factor VII in
seven adult patients with severe refractory HC and prior
exposure to cyclophosphamide or ifosfamide. Six of the seven
patients achieved a response: four complete responses and two
partial responses. Although there was no serious adverse
event, the response duration was found to be only temporary.
In a multicentre, randomised trial, Pihusch et al. [110]
reported no aggregate beneﬁt in the treatment of various
haemorrhagic complications, including HC, with recombinant
factor VII after HSCT, although post hoc analysis showed an
improvement in the control of bleeding with increased dose.
Aminocaproic acid
Aminocaproic acid has proved to be successful in one small
study of 37 patients with intractable bladder haemorrhage,
most of whom had RT- or cyclophosphamide-induced cystitis.
No side-eﬀects were observed [111].
Other Therapeutic Approaches
Anecdotally, patients with chemical or RT-induced cystitis
are often advised to try cranberry juice, and in some centres,
it is considered the ‘gold standard’ of treatment. A recent
systematic review and meta-analysis of 13 randomised
controlled trials showed that cranberry-containing products
are associated with a protective eﬀect against UTIs [112].
The mechanism is thought to be the adhesion of bacteria to
uroepithelial cells by proanthocyanidins, a compound
present in cranberry [113]. Although earlier studies showed
statistically insigniﬁcant or negative results [114,115], data
from a recent study show that the beneﬁcial eﬀects of
Review
© 2013 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of British Association of Urological Surgeons892
cranberry extract in prevention of LUTS can be seen in
patients with prostate cancer with acute bladder damage
associated with high-dose RT [113]. The authors propose that
because of its strong antioxidant properties, it is possible that
cranberry could attenuate actinic damage to the bladder
mucosa, reducing the inﬂammatory process and, as a
consequence, its symptoms. However, further studies are
warranted [113].
Over the last 15 years, numerous other therapeutic approaches
have been tried and have shown some beneﬁt in the treatment
of HC. These include: botulinum toxin A bladder injections in
patients with refractory RT-induced cystitis and BCG-induced
chemical cystitis [116], intravesical recombinant human
granulocyte-macrophage colony-stimulating factor [117],
neodymium:YAG (yttrium-aluminium-garnet) laser therapy
[118,119], and WF10 (tetrachlorodecaoxide i.v. solution)
therapy [120]. However, the role of many of these treatment
methods remains investigational.
Surgical Approaches to HC
In cases where medical treatment has failed to control HC,
surgical intervention may be the treatment of last resort
[1,121]. Several options have been used, including cutaneous
ureterostomy [121], cystoscopy and diathermy [122], vesical
artery embolization [123–125], and supravesical urinary
diversion with, or without, radical cystectomy [43,126].
Although successful resolution after the various interventions
has been reported in a limited number of case studies
[10,121–125], major surgical procedures in these cases can be
associated with high morbidity and mortality [125], as well as
leading to permanent changes to the anatomy and function of
the genitourinary system [10,127].
Discussion
HC remains a signiﬁcant complication after high-dose
chemo-RT, especially in conjunction with HSCT [7]. However,
there is a wide range of reported incidence due to several
factors including: the type of causal agent, the grading of
bleeding, and discrepancies in deﬁnition criteria [7,23].
Although HC is a potentially severe complication, which can
cause signiﬁcant morbidity and considerable expense due to
prolonged hospitalisation [18], there is no published national
or international consensus on the optimal therapeutic strategy.
The present review has highlighted that the evidence base is
currently limited for the various treatment methods used to
prevent and/or treat HC. Most of the reported studies are
either uncontrolled, non-randomised studies, or small case
series or case reports, and involve few patients who have had
several diﬀerent treatment methods. The two therapeutic
approaches with seemingly the best available evidence are
HBO therapy in the treatment of HC and sodium hyaluronate
in the prevention and treatment of HC.
Several studies have evaluated the use of standard
prophylactic measures, including bladder irrigation and the
use of mesna, to reduce the risk of HC, but the results have
been variable. While bladder irrigation and mesna have been
shown to be eﬀective in preventing HC [44,45], Tsuboi et al.
[19] unexpectedly found that both these prophylactic
measures increased the frequency of HC after HSCT,
particularly when mesna was administered with busulfan.
Therefore, it appears that the standard preventive protocols
do not always satisfactorily protect the patient from bladder
injury [128].
HBO therapy has been shown to have eﬃcacy in the treatment
of patients in whom other forms of management have failed,
with few side-eﬀects [39,86,87,97]; although the number of
HBO treatments administered and characteristics of
hyperbaric exposure diﬀers among the various reports. A
randomised controlled study on the use of HBO for the
treatment of RT-induced HC is currently recruiting patients
[129].Whilst HBO therapy appears an eﬀective treatment
method for HC, the practicalities of longer-term
administration and access/availability issues are potential
barriers to its more widespread use.
In recent years, GAG-replenishment therapy has widened
the therapeutic options for patients with HC [130].
Intravesical installation of sodium hyaluronate has been
used successfully in the prevention and treatment of
chemical- and RT-induced HC. Studies have shown that
sodium hyaluronate can signiﬁcantly relieve bleeding, pain
and dysuria and is well tolerated [61–63,72]. Data from a
small randomised study have shown that it is at least as
eﬀective as HBO at treating RT-induced HC [60]. The
positive eﬃcacy results and apparent lack of side-eﬀects
make sodium hyaluronate a potentially attractive option
for the prevention and treatment of HC secondary to RT
and chemotherapy, particularly in patients already
catheterised.
Several other therapeutic and preventive measures have
also been used in the treatment of HC, e.g. intravesical
prostaglandins, chondroitin sulphate, oestrogen therapy, and
sodium pentosanpolysulphate.Whilst there has been some
reported success with these therapies [39,58,59,91], it is
diﬃcult to draw any ﬁrm conclusions due to the generally
poor quality of the available evidence.
A systematic review and meta-analysis of interventions for
preventing HC in patients undergoing HSCT is currently
being undertaken by the Cochrane Collaboration and it is
hoped that this will provide more conclusive evidence on
the optimum treatment [131]. The lack of robust data and
variability in treatment strategies used highlights the need
for further research, as well as best practice guidance and
consensus on the management of this complication, which can
often be challenging to treat.
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